Nintedanib Accordpharma (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, PDGFR and FGFR—thereby inhibiting fibroblast activity and new blood‑vessel formation. This dual anti‑angiogenic and antifibrotic action reduces tissue scarring in the lungs and limits tumor‑related vascular growth.

The dosage of Nintedanib Accordpharma is determined by the prescribing clinician based on the specific indication, patient characteristics and tolerability. Patients should follow the exact regimen provided by their healthcare professional and not adjust the dose on their own.

Safety of Nintedanib in pregnancy and lactation has not been established. It should be used only if the potential benefit outweighs the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and necessary import documentation.

The primary alternative for fibrotic lung disease is pirfenidone, another antifibrotic agent. While both aim to slow disease progression, Nintedanib targets multiple tyrosine kinases and also has anti‑angiogenic properties, whereas pirfenidone works mainly through modulation of inflammatory pathways. Choice depends on patient tolerance, comorbidities and physician judgment.

Nintedanib Accordpharma should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Nintedanib is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow their prescriber's instructions regarding timing and any dietary considerations to minimise gastrointestinal discomfort.

Serious risks include severe liver injury, major bleeding events, arterial thromboembolism, significant hypertension, and rare gastrointestinal perforation. Patients should be monitored regularly for signs of these complications, and treatment should be discontinued if any serious adverse event occurs.

Nintedanib is contraindicated in patients with severe hepatic impairment, active bleeding disorders, uncontrolled hypertension, or known hypersensitivity to the drug. It should also be avoided in pregnant women unless absolutely necessary, and used with caution in breastfeeding mothers.